Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

Inclusion Criteria:

- Participant is 18 years of age or older.

- Participant is scheduled for standard clinical and/or investigational PET/CT scan or
131I therapy within the Nuclear Medicine Service at Main Hospital.

- Patients must have had pathologic lymph node metastases in the neck, axillary or
inguinal area (do not need to be biopsy proven) from either leukemias, lymphomas: ,
Head and Neck cancers (e.g. tonsillar, nasopharynx, tongue carcinoma, breast cancer or
melanoma;or lymphoma or tonsillar or squamous cell carcinoma with metastases in the
neck region for PET/CT imaging, or thyroid cancer for thyroid ablation therapy. Any
other more infrequent cancer metastasizing with nodal metastasis in the neck, axilla
and inguinal regions to cervical lymph nodes is eligible as well as the primary goal
is to image pathological (i.e. hypermetabolic) lymph nodes.

- Patients with hypermetabolic activity and uptake in the neck,axilla, breast and
inguinal region on scan, defined visually as significant lesion suspicious for
malignancy by a nuclear medicine physician or trainee. (We will include a subset of
patients with normal lymph nodes during screening. This subset of patients will be
imaged as a negative control for this study.)

Exclusion Criteria:

- Patients imaged for Cerenkov luminescence are going to be required to be in a darkened
enclosure for at least 10 minutes and sit still during image acquisition, potentially
covered by a dark cloth in case that the ambient light level remains too high for the
ultra-sensitive camera. Any conditions that would prevent this will exclude the
patients.

- There are any other past medical, physiological or demographic concerns. This includes
any patients with skin blemishes that are present at the dermis over the tumor, as
these are of particular interest for use of this technique.